Development of adjuvant therapy targeted to lipid-derived reactive aldehydes-metabolizing enzymes
Project/Area Number |
25460068
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Biological pharmacy
|
Research Institution | Gifu Pharmaceutical University |
Principal Investigator |
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | シスプラチン / 肺がん / 抗がん剤耐性化 / アルドケト還元酵素 / 抗がん剤耐性 / 抗癌剤耐性 / 肺癌 |
Outline of Final Research Achievements |
In this study, I found up-regulation of aldo-keto reductase (AKR) 1B10, an enzyme that detoxifies lipid-derived reactive aldehydes, by development of cisplatin (CDDP)-resistance in lung cancer cells. In addition, the treatment with CDDP enhanced the nitric oxide production, which may participate in mechanism of the AKR1B10 induction. Furthermore, pretreating with AKR1B10 inhibitor overcame the CDDP resistance, suggesting the availability of the inhibitor in adjuvant therapy for CDDP treatment of lung cancer.
|
Report
(4 results)
Research Products
(35 results)
-
[Journal Article] Up-Regulation of Carbonyl Reductase 1 Renders Development of Doxorubicin Resistance in Human Gastrointestinal Cancers2015
Author(s)
Matsunaga T, Kezuka C, Morikawa Y, Suzuki A, Endo S, Iguchi K, Miura T, Nishinaka T, Terada T, El-Kabbani O, Hara A, Ikari A.
-
Journal Title
Biological and Pharmaceutical Bulletin
Volume: 38
Issue: 9
Pages: 1309-1319
DOI
NAID
ISSN
0918-6158, 1347-5215
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
[Journal Article] Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10.2014
Author(s)
Matsunaga T, Morikawa Y, Haga M, Endo S, Soda M, Yamamura K, El-Kabbani O, Tajima K, Ikari A, Hara A
-
Journal Title
Toxicol. Appl. Pharmacol.
Volume: 278
Issue: 2
Pages: 180-189
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
[Journal Article] Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.2014
Author(s)
Matsunaga T, Yamaji Y, Tomokuni T, Morita H, Morikawa Y, Suzuki A, Yonezawa A, Endo S, Ikari A, Iguchi K, El-Kabbani O, Tajima K, Hara A
-
Journal Title
Free Radic. Res.
Volume: 48
Issue: 11
Pages: 1371-1385
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
[Journal Article] Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for AKR1B102013
Author(s)
Satoshi Endo, Dawei HU, Miho Suyama, Toshiyuki Matsunaga, Kenji Sugimoto, Yuji Matsuya, Ossama El-Kabbani, Kazuo Kuwata, Akira Hara, Yukio Kitade, Naoki Toyooka
-
Journal Title
Bioorganic & Medicinal Chemistry
Volume: 21(21)
Issue: 21
Pages: 6378-6384
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Rabbit 3-hydroxyhexobarbital dehydrogenase is a NADPH-preferring reductase with broad substrate specificity for ketosteroids, prostaglandin D2, and other endogenous and xenobiotic carbonyl compounds2013
Author(s)
Satoshi Endo, Toshiyuki Matsunaga, Atsuko Matsumoto, Yuki Arai, Satoshi Ohno, Ossama El-Kabbani, Kazuo Tajima, Yukio Kitade, Yasuo Bunai, Shigeru Yamano, and Akira Hara
-
Journal Title
Biochem. Pharmacol.
Volume: 86
Issue: 9
Pages: 1366-1375
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-